Research Priorities

Gates MRI focuses on programs aimed at reducing the burden of tuberculosis (TB), malaria,  diarrheal diseases, and maternal, newborn, and child illnesses in low-and-middle-income countries (LMICs). LMICs, a term originally defined by the World Bank 1, are often the most impacted by such diseases.

The institute works through collaborating partners and organizations, coordinating and driving the full spectrum of biopharmaceutical development activities to address substantial global health concerns, for which investment incentives are limited.


Pipeline Overview

We have a total of nine assets across five programs, which include three programs in pre-clinical development, one trial in Phase 1, and five trials in Phase 2. We are currently involved in programs in the following disease and health areas, which are in the phases shown:

Tuberculosis Therapeutics: Pre-clinical, Phase 1, and Phase 2. Tuberculosis Vaccines: Phase 2. Shigella Vaccines: Pre-clinical. Malaria Prophylactic Antibody: Pre-clinical. B. Infantis Probiotic: Phase 3.

Research Priorities

Learn more about our research programs at the Gates MRI by clicking on the icons.


Caused by Plasmodium parasites, spread through the bite of infected Anopheles mosquitoes


An infectious disease caused by Mycobacterium tuberculosis (Mtb) bacteria, spread by bacteria expelled into the air

Diarrheal Diseases

Caused by a number of pathogens and a major cause of mortality in LMICs

Maternal, Newborn and Child Health

Development of treatments that may help lower the rates of newborn and child mortality